Folate-modified lipoplexes delivering the interleukin-12 gene for targeting colon cancer immunogene therapy

Journal of Biomedical Nanotechnology

Volumn 11, Issue 11, 2015, Pages 2011-2023

  Luo, Min ^a   Liang, Xiao ^a   Luo, Shun Tao ^a   Wei, Xia Wei ^a   Liu, Ting ^a   Ren, Jun ^a   Ma, Cui Cui ^a   Yang, Yu Han ^a   Wang, Bi Lan ^a   Liu, Li ^a   Song, Xiang Rong ^a   He, Zhi Yao ^a   Wei, Yu Quan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Colon Cancer; Folate Receptor ; Gene Therapy; Immunotherapy; Interleukin 12; Lipoplex

Indexed keywords

CELL DEATH; COMPUTERIZED TOMOGRAPHY; GENE THERAPY; GENES; HEALTH RISKS; HISTOLOGY; LIPOSOMES; PHYSIOLOGY; TISSUE; TUMORS;

COLON CANCER; FOLATE RECEPTOR; IMMUNOTHERAPY; INTERLEUKIN-12; LIPOPLEXES;

DISEASES;

CD31 ANTIGEN; FOLATE RECEPTOR 1; FOLIC ACID; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 12P70; LIPOPLEX; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MESSENGER RNA; PLASMID DNA; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; CYTOKINE; LIPOSOME;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER GENE THERAPY; CANCER GROWTH; CANCER IMMUNOGENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER LOCALIZATION; CANCER SIZE; CAPILLARY DENSITY; CELL ACTIVITY; CELL STRUCTURE; CHEMICAL STRUCTURE; COLON CANCER; COLON CARCINOMA; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DOWN REGULATION; FEMALE; GENE DELIVERY SYSTEM; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MACROPHAGE; MALIGNANT ASCITES; MOLECULAR INTERACTION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; PROTEIN INDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; UPREGULATION; URINARY EXCRETION; ZETA POTENTIAL; ANIMAL; CHEMISTRY; COLON TUMOR; DRUG DELIVERY SYSTEM; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; IMMUNOTHERAPY; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYTOKINES; DOWN-REGULATION; DRUG DELIVERY SYSTEMS; FOLATE RECEPTOR 1; FOLIC ACID; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; IMMUNOTHERAPY; INTERLEUKIN-12; LIPOSOMES; MICE;

EID: 84956575592     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2015.2136     Document Type: Article

References (63)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal, Cancer statistics. CA Cancer J. Clin. 64, 9 (2014).
2. R. Siegel, C. Desantis, and A. Jemal, Colorectal cancer statistics. CA Cancer J. Clin. 64, 104 (2014).
3. H. Brenner, M. Kloor, and C. P. Pox, Colorectal cancer. Lancet. 383, 1490 (2014).
4. I. Thomassen, Y. R. van Gestel, V. E. Lemmens, and I. H. de Hingh, Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from col-orectal origin. Dis. Colon Rectum. 56, 1373 (2013).
5. D. C. Damin and A. R. Lazzaron, Evolving treatment strategies for colorectal cancer: A critical review of current therapeutic options. World J. Gastroenterol. 20, 877 (2014).
6. J. Prados, C. Melguizo, H. Roldan, P. J. Alvarez, R. Ortiz, J. L. Arias, and A. Aranega, RNA interference in the treatment of colon cancer. Biodrugs. 27, 317 (2013).
7. E. P. Mitchell, Targeted therapy for metastatic colorectal cancer: Role of aflibercept. Clin. Colorectal Cancer. 12, 73 (2013).
8. B. Xiang, A. E. Snook, M. S. Magee, and S. A. Waldman, Colorectal cancer immunotherapy. Discov. Med. 15, 301 (2013).
9. W. Lasek, R. Zagozdzon, and M. Jakobisiak, Interleukin 12: Still a promising candidate for tumor immunotherapy? Cancer Immunol. Immunother. 63, 419 (2014).
10. G. Trinchieri, Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133 (2003).
11. J. P. Leonard, M. L. Sherman, G. L. Fisher, L. J. Buchanan, G. Larsen, M. B. Atkins, J. A. Sosman, J. P. Dutcher, N. J. Vogelzang, and J. L. Ryan, Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90, 2541 (1997).
12. I. Melero, G. Mazzolini, I. Narvaiza, C. Qian, L. Chen, and J. Prieto, IL-12 gene therapy for cancer: In synergy with other immunothera-pies. Trends Immunol. 22, 113 (2001).
13. L. Z. Wei, Y. Xu, E. M. Nelles, C. Furlonger, J. C. Wang, M. A. Di Grappa, R. Khokha, J. A. Medin, and C. J. Paige, Localized interleukin-12 delivery for immunotherapy of solid tumours. J. Cell. Mol. Med. 17, 1465 (2013).
14. S. D. Reed and S. Li, Pre-clinical toxicity assessment of tumor-targeted interleukin-12 low-intensity electrogenetherapy. Cancer Gene Ther. 18, 265 (2011).
15. M. L. Lucas, L. Heller, D. Coppola, and R. Heller, IL-12 plas-mid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol. Ther. 5, 668 (2002).
16. S. Denies, L. Cicchelero, I. Van Audenhove, and N. N. Sanders, Combination of interleukin-12 gene therapy, metronomic cyclophos-phamide and DNA cancer vaccination directs all arms of the immune system towards tumor eradication. J. Control. Release 187, 175 (2014).
17. R. Suzuki, E. Namai, Y. Oda, N. Nishiie, S. Otake, R. Koshima, K. Hirata, Y. Taira, N. Utoguchi, Y. Negishi, S. Nakagawa, and K. Maruyama, Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure. J. Control. Release. 142, 245 (2010).
18. S. Hallaj-Nezhadi, H. Valizadeh, B. Baradaran, F. Dobakhti, and F. Lotfipour, Preparation and characterization of gelatin nanoparti-cles containing pDNA encoding IL-12 and their expression in CT-26 carcinoma cells. Future Oncol. 9, 1195 (2013).
19. J. Li, Z. He, S. Yu, S. Li, Q. Ma, Y. Yu, J. Zhang, R. Li, Y. Zheng, G. He, and X. Song, Micelles based on methoxy poly(ethylene glycol) cholesterol conjugate for controlled and targeted drug delivery of a poorly water soluble drug. J. Biomed Nanotechnol. 8, 809 (2012).
20. J. R. Rodriguez-Madoz, M. Zabala, M. Alfaro, J. Prieto, M. G. Kramer, and C. Smerdou, Short-term intratumoral interleukin-12 expressed from an alphaviral vector is sufficient to induce an efficient antitumoral response against spontaneous hepatocellular carcinomas. Hum. Gene Ther. 25, 132 (2014).
21. T. H. Kim, H. Jin, H. W. Kim, M. H. Cho, and C. S. Cho, Mannosy-lated chitosan nanoparticle-based cytokine gene therapy suppressed cancer growth in BALB/c mice bearing CT-26 carcinoma cells. Mol. Cancer Ther. 5, 1723 (2006).
22. Z. L. Nie, Y. Q. Pan, B. S. He, L. Gu, L. P. Chen, R. Li, Y. Q. Xu, T. Y. Gao, G. Q. Song, A. R. Hoffman, S. K. Wang, and J. F. Hu, Gene therapy for colorectal cancer by an oncolytic adenovirus that targets loss of the insulin-like growth factor 2 imprinting system. Mol. Cancer. 11, 86 (2012).
23. J. Sudimack and R. J. Lee, Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 41, 147 (2000).
24. M. K. Siu, D. S. Kong, H. Y. Chan, E. S. Wong, P. P. Ip, L. Jiang, H. Y. Ngan, X. F. Le, and A. N. Cheung, Paradoxical impact of two folate receptors, FRalpha and RFC, in ovarian cancer: Effect on cell proliferation, invasion and clinical outcome. PLoS One 7, e47201 (2012).
25. W. J. Syu, H. P. Yu, C. Y. Hsu, Y. C. Rajan, Y. H. Hsu, Y. C. Chang, W. Y. Hsieh, C. H. Wang, and P. S. Lai, Improved photodynamic cancer treatment by folate-conjugated polymeric micelles in a KB xenografted animal model. Small 8, 2060 (2012).
26. P. S. Low and S. A. Kularatne, Folate-targeted therapeutic and imaging agents for cancer. Curr. Opin. Chem. Biol. 13, 256 (2009).
27. L. Teng, J. Xie, L. Teng, and R. J. Lee, Clinical translation of folate receptor-targeted therapeutics. Expert Opin Drug Deliv. 9, 901 (2012).
28. J. Shia, D. S. Klimstra, J. R. Nitzkorski, P. S. Low, M. Gonen, R. Landmann, M. R. Weiser, W. A. Franklin, F. G. Prendergast, L. Murphy, L. H. Tang, L. Temple, J. G. Guillem, W. D. Wong, and P. B. Paty, Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: Patterns and biological significance. Hum. Pathol. 39, 498 (2008).
29. J. P. Tiernan, S. L. Perry, E. T. Verghese, N. P. West, S. Yeluri, D. G. Jayne, and T. A. Hughes, Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. Br. J. Cancer. 108, 662 (2013).
30. L. Zhang, W Zhu, C. Yang, H. Guo, A. Yu, J. Ji, Y. Gao, M. Sun, and G. Zhai, A novel folate-modified self-microemulsifying drug delivery system of curcumin for colon targeting. Int. J. Nanomedicine 7, 151 (2012).
31. Z. He, Y. Yu, Y. Zhang, Y. Yan, Y. Zheng, J. He, Y. Xie, G. He, Y. Wei, and X. Song, Gene delivery with active targeting to ovarian cancer cells mediated by folate receptor a. J. Biomed. Nanotechnol. 9, 833 (2013).
32. Z. Y. He, X. Zheng, X. H. Wu, X. R. Song, G. He, W F. Wu, S. Yu, S. J. Mao, and Y. Q. Wei, Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery. Int. J. Pharm. 397, 147 (2010).
33. Z.-Y. He, X.-W. Wei, M. Luo, S.-T. Luo, Y. Yang, Y.-Y. Yu, Y. Chen, C.-C. Ma, X. Liang, F.-C. Guo, T.-H. Ye, H.-S. Shi, G.-B. Shen, W. Wang, F.-M. Gong, G. He, X. Zhao, X.-R. Song, and Y.-Q. Wei, Folate-linked lipoplexes for short hairpin RNA targeting Claudin-3 delivery in ovarian cancer xenografts. J. Control. Release 172, 679 (2013).
34. Y. Lu, Y. Q. Wei, L. Tian, X. Zhao, L. Yang, B. Hu, B. Kan, Y. J. Wen, F. Liu, H. X. Deng, J. Li, Y. Q. Mao, S. Lei, M. J. Huang, F. Peng, Y. Jiang, H. Zhou, L. Q. Zhou, and F. Luo, Immuno-gene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor. J. Immunol. 170, 3162 (2003).
35. W. G. Yu, M. Ogawa, J. Mu, K. Umehara, T. Tsujimura, H. Fujiwara, and T. Hamaoka, IL-12-induced tumor regression correlates with in situ activity of IFN-gamma produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways. J. Leukoc. Biol. 62, 450 (1997).
36. G. Trinchieri, Immunobiology of interleukin-12. Immunol. Res. 17, 269 (1998).
37. E. E. Voest, B. M. Kenyon, M. S. O'Reilly, G. Truitt, R. J. D'Amato, and J. Folkman, Inhibition of angiogenesis in vivo by interleukin 12. J. Natl. Cancer Inst. 87, 581 (1995).
38. A. Sica and V. Bronte, Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117, 1155 (2007).
39. A. Sica, P. Larghi, A. Mancino, L. Rubino, C. Porta, M. G. Totaro, M. Rimoldi, S. K. Biswas, P. Allavena, and A. Mantovani, Macrophage polarization in tumour progression. Semin. Cancer Biol. 18, 349 (2008).
40. G. Alter, J. M. Malenfant, and M. Altfeld, CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294, 15 (2004).
41. E. Aktas, U. C. Kucuksezer, S. Bilgic, G. Erten, and G. Deniz, Relationship between CD107a expression and cytotoxic activity. Cell Immunol. 254, 149 (2009).
42. M. K. Brenner, S. Gottschalk, A. M. Leen, and J. F. Vera, Is cancer gene therapy an empty suit? Lancet Oncol. 14, e447 (2013).
43. J. Han, Q. Wang, Z. Zhang, T. Gong, and X. Sun, Cationic bovine serum albumin based self-assembled nanoparticles as siRNA delivery vector for treating lung metastatic cancer. Small 10, 524 (2014).
44. X. Zhao, A. Bose, H. Komita, J. L. Taylor, M. Kawabe, N. Chi, L. Spokas, D. B. Lowe, C. Goldbach, S. Alber, S. C. Watkins, L. H. Butterfield, P. Kalinski, J. M. Kirkwood, and W. J. Storkus, Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. Mol. Ther. 19, 805 (2011).
45. Y. Qu, L. Chen, D. B. Lowe, W. J. Storkus, and J. L. Taylor, Combined Tbet and IL12 gene therapy elicits and recruits superior anti-tumor immunity in vivo. Mol. Ther. 20, 644 (2012).
46. H. Tian, J. Chen, and X. Chen, Nanoparticles for Gene Delivery. Small 9, 2034 (2013).
47. S. Dadashzadeh, N. Mirahmadi, M. H. Babaei, and A. M. Vali, Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge. J. Control. Release 148, 177 (2010).
48. H. Lv, S. Zhang, B. Wang, S. Cui, and J. Yan, Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 114, 100 (2006).
49. C. L. Nastala, H. D. Edington, T. G. McKinney, H. Tahara, M. A. Nalesnik, M. J. Brunda, M. K. Gately, S. F. Wolf, R. D. Schreiber, and W. J. Storkus, Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J. Immunol. 153, 1697 (1994).
50. A. Tietje, J. Li, X. Yu, and Y. Wei, MULT1E/mIL-12: A novel bifunctional protein for natural killer cell activation. Gene Ther. 21, 468 (2014).
51. A. Uemura, T. Takehara, T. Miyagi, T. Suzuki, T. Tatsumi, K. Ohkawa, T. Kanto, N. Hiramatsu, and N. Hayashi, Natural killer cell is a major producer of interferon gamma that is critical for the IL-12-induced anti-tumor effect in mice. Cancer Immunol. Immunother. 59, 453 (2010).
52. M. S. Jhaveri, A. S. Rait, K. N. Chung, J. B. Trepel, and E. H. Chang, Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol. Cancer Ther. 3, 1505 (2004).
53. M. Figini, R. Ferri, D. Mezzanzanica, M. Bagnoli, E. Luison, S. Miotti, and S. Canevari, Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Ther. 10, 1018 (2003).
54. P. Rouhi, S. L. Lee, Z. Cao, E. M. Hedlund, L. D. Jensen, and Y. Cao, Pathological angiogenesis facilitates tumor cell dissemination and metastasis. Cell Cycle 9, 913 (2010).
55. D. G. Duda, M. Sunamura, L. Lozonschi, T. Kodama, S. Egawa, G. Matsumoto, H. Shimamura, K. Shibuya, K. Takeda, and S. Matsuno, Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res. 60, 1111 (2000).
56. C. Kanegane, C. Sgadari, H. Kanegane, J. Teruya-Feldstein, L. Yao, G. Gupta, J. M. Farber, F. Liao, L. Liu, and G. Tosato, Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J. Leukoc. Biol. 64, 384 (1998).
57. R. van Horssen, T. L. Ten Hagen, and A. M. Eggermont, TNF-alpha in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist. 11, 397 (2006).
58. S. P. Kerkar, R. S. Goldszmid, P. Muranski, D. Chinnasamy, Z. Yu, R. N. Reger, A. J. Leonardi, R. A. Morgan, E. Wang, F. M. Marincola, G. Trinchieri, S. A. Rosenberg, and N. P. Restifo, IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J. Clin. Invest. 121, 4746 (2011).
59. M. Gonzalez-Aparicio, P. Alzuguren, I. Mauleon, J. Medina-Echeverz, S. Hervas-Stubbs, U. Mancheno, P. Berraondo, J. Crettaz, G. Gonzalez-Aseguinolaza, J. Prieto, and R. Hernandez-Alcoceba, Oxaliplatin in combination with liver-specific expression of inter-leukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice. Gut. 60, 341 (2011).
60. X. F. Wang, H. S. Wang, F. Zhang, Q. Guo, H. Wang, K. F. Wang, G. Zhang, X. Z. Bu, S. H. Cai, and J. Du, Nodal promotes the generation of M2-like macrophages and downregu-lates the expression of IL-12. Eur. J. Immunol. 173-183, 173 (2014).
61. S. K. Watkins, N. K. Egilmez, J. Suttles, and R. D. Stout, IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J. Immunol. 178, 1357 (2007).
62. Y. Luo, H. Zhou, J. Krueger, C. Kaplan, S. H. Lee, C. Dolman, D. Markowitz, W. Wu, C. Liu, R. A. Reisfeld, and R. Xiang, Targeting tumor-associated macrophages as a novel strategy against breast cancer. J. Clin. Invest. 116, 2132 (2006).
63. M. Santoni, F. Massari, C. Amantini, M. Nabissi, F. Maines, L. Burattini, R. Berardi, G. Santoni, R. Montironi, G. Tortora, and S. Cascinu, Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol. Immunother. 62, 1757 (2013).